johncohen- I have a slightly different view. In my opinion- and having spoken to people who know a lot about osl- the problem was osl totally underestimating (or ignorance of) the regulatory requirements and setting up the market in 2014/2015 to believe CE was a breeze and they were in fast track. Then they realised they’d got it wrong, need to do a trial as they didn’t have enough data for CE so off they went to do panco. For a trial of that type the time it took was actually probably about par so I don’t think they were dragging their feet at that stage because you can’t always predict patient recruitment into a trial. Then of course they spent another year having to reverse the CE rejection until finally scraping through last year . But you could also say the company as it existed before the last CEO (Kenny) spent 2 years doing nothing. Or the company in England that designed the original device started development then dropped it for some reason and that’s many many years ago. so it’s a troubled path. And yes in that time other treatments have evolved.
concerning RCT you’re right, I’ve looked at their announcements from last year and $7m raised was supposed to be for US trial. But there’s no design that I’ve seen. They also told market FDA approval for pancreatic cancer in 2022/23 but you can forget that. To meet that date in my opinion they’d have needed to start RCT by 2018. And that’s assuming a positive trial. “Breakthrough” designation otherwise means little. $7million won’t get them a RCT. Depending on patient numbers (I’ve heard 200 or more) I think they’d be looking at costs at least 5 X that amount, and that’s conservative. Could be 10x. . You could go back through their financials to see how much they spent on R&D with panco to help gauge the likely costs involved with larger trial.
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
johncohen- I have a slightly different view. In my opinion- and...
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
1.1¢ |
Change
0.001(4.76%) |
Mkt cap ! $41.62M |
Open | High | Low | Value | Volume |
1.0¢ | 1.1¢ | 1.0¢ | $36.16K | 3.384M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 14154999 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 5667943 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 14154999 | 0.010 |
21 | 12098472 | 0.009 |
9 | 6587500 | 0.008 |
7 | 3264285 | 0.007 |
9 | 8595001 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 5667943 | 6 |
0.012 | 6817838 | 11 |
0.013 | 11057332 | 6 |
0.014 | 5769139 | 8 |
0.015 | 8500000 | 3 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online